Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XmAb24306 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Dose escalation | EXPERIMENTAL | Participants will receive escalating doses of XmAb24306 with daratumumab up to the maximum tolerated dose (MTD) |
| Dose expansion | EXPERIMENTAL | Participants will receive XmAb24306 with daratumumab at the recommended phase 2 dose (RP2D) |
| Phase 1a Dose Escalation | EXPERIMENTAL | Participants will receive XmAb24306 until study treatment discontinuation or study termination. |
| Phase 1a Dose Expansion | EXPERIMENTAL | Participants will receive XmAb24306 until study treatment discontinuation or study termination. |
| Phase 1b Dose Escalation | EXPERIMENTAL | Participants will receive XmAb24306 and atezolizumab until study treatment discontinuation or study termination. |
| Phase 1b Dose Expansion | EXPERIMENTAL | Participants will receive XmAb24306 and atezolizumab until study treatment discontinuation or study termination. |
| Name | Type | Description |
|---|---|---|
| XmAb24306 | DRUG | XmAb24306 will be given via intravenous (IV) infusion |
| Daratumumab | DRUG | Participants will receive daratumumab via subcutaneous (SC) injection every week for Cycles 1-4, every 2 weeks for Cycles 5-12, and every 4 weeks thereafter (cycle length = 2 weeks for Cycles 1-12 and 4 weeks thereafter) |
| Atezolizumab | DRUG | Participants will receive IV XmAb24306 followed by IV atezolizumab |
Inclusion Criteria: * Life expectancy of at least 12 weeks * Measurable disease, as defined by the protocol * Participants must have received a minimum of 3 prior lines of therapy, including at least one PI, one IMiD, and an anti-CD38 monoclonal antibody * Best response of stable disease or better ...
Top 20 of 25 competitors
XmAb24306 is an investigational oncology therapy being studied for solid tumors and multiple myeloma. It is in Phase 1 clinical development for locally advanced or metastatic solid tumors and for relapsed/refractory multiple myeloma. The drug is not approved and remains under clinical investigation.
XmAb24306 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials of the drug in oncology indications including solid tumors and multiple myeloma.
XmAb24306 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 1 studies have been completed, one in solid tumors and one in multiple myeloma.
XmAb24306 has been studied in two completed Phase 1 trials. NCT04250155 evaluated the drug as a single agent and in combination with atezolizumab in solid tumors. NCT05243342 evaluated it in combination with daratumumab in relapsed/refractory multiple myeloma.
Yes, XmAb24306 and XMAB24306 refer to the same drug. The capitalization of the name varies in clinical trial records, but both spellings denote the same investigational oncology therapy being developed by Roche.